Navigation path

AMVTN/AMANET


Malaria

African Malaria Vaccine Testing Network
Framework programme:
5
Project number:
ICA4-CT-2002-10033
EC contribution:
€ 1 000 000
Duration:
36 months
Type:
CA
Starting date:
1 November 2002

Summary:

Over the past six years, AMVTN has established itself as a leading pan-African network building human capacity in malaria vaccine research, development and clinical trials. AMVTN's courses, workshops and seminars are oversubscribed, reflecting the need for continuous and expanded human capacity building. The proposed activities will benefit African prospective study sites by complementing a recent grant of €3.1 million by the Government of the Netherlands to AMVTN's essential capacity strengthening in health research ethics, GCP, GLP, vaccinology, monitoring, data management, exchange of clinical trialists and establishment of an essential malaria vaccine database. Collective strengths and expertise of African and European scientists will ensure smooth cooperation and adherence to ethical principles in the evaluation of intervention trials.

Objectives:

Malaria is the leading public health enemy in sub-Saharan Africa. Current tools for its management, prevention and control are turning blunt. Malaria vaccines are badly needed, promising new tools. The aim of this concerted action is:

1) to consolidate, strengthen and expand the already existing platform for the proper planning and effective coordination of clinical and field evaluation of malaria vaccines in Africa

2) to ensure smooth transfer of newly manufactured malaria vaccine candidates (after phase Ia testing) to African malaria vaccine trial sites through the collaboration of an African malaria network and participating African and European institutions

3) to build capacity, particularly at prospective trial sites, in the form of training workshops (GLP, GCP, SOP, ethics, vaccinology, data management, etc.), exchange of trialists and data exchange

4) to further develop AMVTN's secretariat to a focal point for information and exchange of data on malaria vaccine trial activities.

[+] Read More